Mobile terms and conditions

inLighten alerts

Opt in to receive patient support messages from the inLighten™ Patient Support program. Message frequency varies. Message and data rates may apply.

By opting in, you consent to receive autodialed text messages from inLighten. Agreeing to receive text messages is not required to participate in inLighten. 

By signing up, you are confirming you are over the age of 18.

STOP information

Text STOP to 31643 to stop receiving inLighten alerts from inLighten. You will receive a confirmation text.

HELP information

For additional information, text HELP to 31643 or contact 833-544-4800.

Supported carriers are:

AT&T, Verizon Wireless, T-Mobile/Sprint/Metro PCS, CellCom USA, C Spire Wireless, U.S. Cellular, Carolina West Wireless (CWW), Google Voice, Claro Puerto Rico, ACS/Alaska, Advantage Cellular (DTC Wireless), Appalachian Wireless, Bluegrass Cellular, Cellular Network Partnership (PIONEER), Cellular One of East Central Illinois, Chat Mobility USA, Coral Wireless (Mobi PCS), Element Mobile (Flat Wireless), Epic Touch (Elkhart Telephone), GCI Communications Corp, Golden State Cellular, Illinois Valley Cellular (IV Cellular), iWireless (IOWA Wireless), Nex-Tech Wireless, MTA Communications, MTPCS (Cellular One Nation), Cross Telephone Company (MBO Wireless), Duet IP (Maximum Communications New Core Wireless), Inland Cellular Telephone Company, Immix (Keystone Wireless), Mosaic (Consolidated or CTC Telecom), Northwest Missouri Cellular Limited, Peoples Wireless, Panhandle Telecommunications Systems (PTCI), RINA, Revol Wireless USA, SI Wireless/Mobile Nation, SRT Wireless, Texas RSA 3 Ltd (Plateau Wireless), Thumb Cellular, United Wireless, Union Telephone Company (Union Wireless), Viaero Wireless, West Central Wireless (5 Star Wireless), Sagebrush Cellular (Nemont), Pine Cellular, Aio Wireless/Cricket, SouthernLinc, Bandwidth, Copper Valley, Leaco, CableVision, Buffalo Wireless, Chariton Valley Cellular, Pine Belt Wireless, Atlantic Tele-Network International (ATN). T-Mobile is not liable for delayed or undelivered messages. We take your privacy seriously. Please visit insmed.com/privacy-policy to review our privacy policy.

IMPORTANT SAFETY INFORMATION AND INDICATION

Before taking BRINSUPRI, tell your healthcare provider about all of your medical conditions, including if you:

  • have recently received or are scheduled to receive any live attenuated vaccinations.

  • are pregnant or plan to become pregnant. It is not known if BRINSUPRI will harm your unborn baby.

  • are breastfeeding or plan to breastfeed. It is not known if BRINSUPRI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during this time.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not change or stop your medicines unless your healthcare provider tells you to.

BRINSUPRI may cause serious side effects including:

  • Skin problems. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination, if needed. 

  • Dental problems. Get regular dental checkups while taking BRINSUPRI. Brush and clean your teeth as recommended by your dentist. Tell your healthcare provider and contact your dentist if you experience new gum (gingival) or teeth (dental) symptoms.

Common side effects of BRINSUPRI

The most common side effects of BRINSUPRI include upper respiratory tract infection, headache, rash, dry skin, small areas of skin thickening (hyperkeratosis), and high blood pressure (hypertension).

Less common side effects include abnormal liver blood test, hair loss (alopecia), and skin cancers.

These are not all of the possible side effects of BRINSUPRI.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is BRINSUPRI?

BRINSUPRI is a prescription medicine used to treat non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years of age and older. It is not known if BRINSUPRI is safe and effective in children under 12 years of age.

Please see full Prescribing Information and Patient Information.